XOMA (NASDAQ:XOMA) Rating Lowered to “Sell” at StockNews.com

StockNews.com lowered shares of XOMA (NASDAQ:XOMA) from a hold rating to a sell rating in a report issued on Friday morning.

Separately, HC Wainwright reiterated a “buy” rating and issued a $123.00 target price on shares of XOMA in a research report on Friday, December 13th.

XOMA Stock Performance

XOMA stock opened at $26.30 on Friday. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. XOMA has a 1-year low of $18.24 and a 1-year high of $35.00. The business has a 50-day moving average price of $29.76 and a 200 day moving average price of $27.85. The company has a market capitalization of $309.89 million, a P/E ratio of -7.56 and a beta of 0.88.

Insider Buying and Selling at XOMA

In related news, CEO Owen Hughes sold 21,881 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the sale, the chief executive officer now directly owns 34,979 shares of the company’s stock, valued at $1,047,621.05. This represents a 38.48 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its position in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares during the last quarter. Barclays PLC boosted its holdings in XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after acquiring an additional 8,447 shares during the last quarter. Ellsworth Advisors LLC purchased a new stake in shares of XOMA during the 3rd quarter worth about $516,000. Finally, Bank of New York Mellon Corp increased its position in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after acquiring an additional 1,968 shares in the last quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.